Pharmaceutical Technology Department, National Research Centre, El-Buhouth St., Dokki, Cairo, 12622, Egypt.
Pharmacology Department, National Research Centre, El-Buhouth St., Dokki, Cairo, 12622, Egypt.
Sci Rep. 2024 Oct 11;14(1):23799. doi: 10.1038/s41598-024-73567-6.
Rutin, a flavone glycoside, has shown to have a significant beneficial kidney protection effect in drug-induced nephropathy. However, its poor solubility and low oral bioavailability have limited its pharmacological applications. This study aimed at formulating rutin-loaded bilosomes to enhance the renal protective effect of rutin for oral application. Rutin-loaded bilosomes were developed using thin-film hydration technique. The prepared formulations were characterized by entrapment efficiency percentage (EE%), vesicular size (VS) and zeta potential (ZP) measurement. The developed formula exhibited moderate EE%, ranging from 20.02 ± 2.85 to 48.57 ± 3.57%, suitable VS results that ranged from 502.1 ± 36 to 665.1 ± 45 nm and high ZP values (≤ -41.4 ± 7.27 mV). Transmission electron microscopy revealed the spherical shape of the developed bilosomes. The in-vitro release study revealed prolonged release of rutin from bilosomes, relative to free drug. F, prepared using the molar ratio span 60: cholesterol: sodium cholate 1:1:0.5, was selected for further investigations as it showed the highest EE%, smallest VS, optimum ZP, and persistent release profile. In-vivo studies were performed on drug-induced nephropathy in rats. Acute renal failure was induced using a single dose of potassium dichromate (PDC; 15 mg/kg; i.p). The selected formulation, F2, alleviated kidney dysfunction, oxidative stress and inflammation via decreasing MDA, TNF-α and TGF-β and increasing GSH. In addition, F2 promoted Akt/PI3K activation against PDC-induced acute renal failure. Histopathology results came in accordance with in-vivo results. Thus, bilosomes could be considered a potential delivery system for enhancing the oral delivery and kidney protection activity of rutin.
芦丁是一种黄酮糖苷,已被证明在药物诱导的肾病中有显著的肾脏保护作用。然而,其较差的溶解度和低口服生物利用度限制了其在药理学上的应用。本研究旨在通过制备芦丁载药双层囊泡来增强芦丁的口服肾脏保护作用。采用薄膜水化法制备芦丁载药双层囊泡。通过测定包封率(EE%)、囊泡粒径(VS)和 zeta 电位(ZP)对所制备的载药双层囊泡进行了表征。结果表明,所制备的载药双层囊泡具有适中的 EE%(20.02±2.85%至 48.57±3.57%),合适的 VS 结果(502.1±36nm 至 665.1±45nm)和高 ZP 值(≤-41.4±7.27mV)。透射电子显微镜显示所制备的双层囊泡为球形。体外释放研究表明,芦丁从双层囊泡中的释放时间较游离药物延长。F 载药双层囊泡(摩尔比Span 60:胆固醇:脱氧胆酸钠为 1:1:0.5)具有最高的 EE%、最小的 VS、最佳的 ZP 和持续释放的特征,因此被选为进一步研究的候选配方。在大鼠药物诱导的肾病模型中进行了体内研究。通过单次腹腔注射重铬酸钾(PDC;15mg/kg)诱导急性肾衰竭。所选的 F2 配方通过降低 MDA、TNF-α 和 TGF-β,增加 GSH,减轻了肾功能障碍、氧化应激和炎症。此外,F2 还促进了 Akt/PI3K 的激活,从而对抗 PDC 诱导的急性肾损伤。组织病理学结果与体内结果一致。因此,双层囊泡可以被认为是一种有潜力的给药系统,能够增强芦丁的口服递送和肾脏保护活性。